Molecular Imaging Launches New Name; Presents Posters at the American Association of Cancer Research Annual Meeting 2016

April 6, 2016
April, 2016

Ann Arbor, Mich., April 7, 2016 (BUSINESS WIRE) — Molecular Imaging, Inc. (MI), a leading preclinical oncology contract research organization, announces that, as of April 16, 2016, its name will change to “MI Bioresearch,” with the tagline “Advancing Your Preclinical Oncology.” The company will unveil its new branding at the American Association of Cancer Research (AACR) Annual Meeting April 16-20 in New Orleans.

“Our new name and brand reflect the company’s overall growth, expansion and excellence in providing a wide array of client-relevant preclinical oncology services,” said Tom Ludlam Jr., President and CEO.

Examples of the company’s capabilities will be on display at two poster presentations during AACR. On April 19, Matt Thayer, Senior Assistant Scientist, will present “In Depth Myeloid Cell Characterization in the Murine Syngeneic CT26 Colon Carcinoma Model by 10-color Flow Cytometry.” On April 20, Maryland Franklin, Ph.D., Vice President, Scientific Development, will present “Evaluation of the Immune Response Following Treatment With Anti-CTLA-4 Antibody, Radiation Therapy, or the Combination in a Murine Model of Breast Cancer.”

Since its inception in 2003, MI has broadened its oncology offerings to become a premier provider of in vitro services, including complex flow cytometry; in vivo pharmacology services, including expansion into immuno-oncology; and focal irradiation services using the Xstrahl SARRP system. These complement MI’s market-leading position in the provision of in vivo imaging services across all relevant modalities.

“Today, MI offers the most relevant models and services to interrogate oncology pharmacology. We are much more than an imaging services provider. We work closely with our clients to provide the tools, services and consultative support necessary to reach their next breakthrough in oncology drug discovery and development,” said Ludlam. “Our new branding emphasizes the three areas of excellence our clients recognize with MI: preclinical know-how, pharmacology expertise and data-driven insight.”

To learn more about Molecular Imaging or the poster sessions, or to schedule a meeting, contact or visit

About Molecular Imaging
Molecular Imaging is the premier preclinical oncology service provider, leveraging focused scientific expertise and the widest breadth of tools and techniques to interrogate pharmacology in human and syngeneic tumor models, including an expansive bank of cancer cell line models and the industry’s most sophisticated multi-modality imaging capabilities. Your critical oncology research deserves proven pharmacology expertise, leading technology and superior data-driven insight. For more information, visit or email